Author(s)
Morla González, MarinaKeywords
Patentes farmacéuticasPropiedad intelectual
Derecho a la salud
Ética en las patentes
Salud pública
Medicamento
Medicamentos genéricos
TTIP
Responsabilidad social corporativa
Orden público
Moralidad
Bioderecho
Biotecnología
Pharmaceutical patents
Intellectual property
Health right
Ethics in patents
Public health
Drugs
Generic drugs
Coroporative social responsibility
Public order
Morality
Biolaw
Biotechnology
Full record
Show full item recordOnline Access
https://idus.us.es/xmlui/handle/11441/59027Abstract
El objetivo de este estudio es realizar un análisis de cómo un reparto insostenible de recursos dificulta el acceso a medicamentos a la sociedad en países en vías de desarrollo y subdesarrollados. Este análisis encuentra su eje en la tensión que se crea entre las patentes farmacéuticas a través de las cuales se hace efectivo el derecho de propiedad intelectual de las empresas farmacéuticas, y el derecho a la salud de la sociedad en necesidad de adquirir medicamentos. Se reflexionará acerca de la interpretación de las distintas leyes y regulaciones relativas a este asunto que se han desarrollado a lo largo de la historia, así como acerca de las consideraciones éticas ligadas a las mismas. Del mismo modo, se prestará atención a la situación actual y perspectivas de futuro, principalmente en relación a la aproximación entre Estados Unidos y Europa a través de la firma de Tratados y a la responsabilidad social corporativa de las empresas farmacéuticasThe aim of this paper is to analyse how the unsustainable resources
 distribution generates difficulties in the access to medicines in developing and underdeveloped countries. This analysis mainly focuses on the strain between pharmaceutical patents through which pharmaceutical companies make their intellectual property rights effective, and the right of society for a health service. The aim is also to reflect on the interpretation of the different regulations related to this issue developed throughout history, and also about their ethical considerations. Likewise, this analysis pays attention to the current situation and future perspectives, mainly about the closeness between the USA and Europe through Treaty signings and also pharmaceutical companies corporative social responsibility
Date
2017-05-02Type
info:eu-repo/semantics/articleIdentifier
oai:idus.us.es:11441/59027https://idus.us.es/xmlui/handle/11441/59027
Copyright/License
Attribution-NonCommercial-NoDerivatives 4.0 InternacionalCollections
Related items
Showing items related by title, author, creator and subject.
-
Promoting Intellectual Property Monetization in Developing Countries : A Review of Issues and Strategies to Support Knowledge-driven GrowthGhafele, Roya; Gibert, Benjamin (World Bank, Washington, DC, 2012-07)This paper outlines and evaluates
 several intellectual property monetization strategies
 available to patent holders in developing countries that
 help generate domestic innovation and knowledge-driven
 growth by promoting more active technology markets. Based on
 a review of World Intellectual Property Report indicators,
 the patent ownership gap between a sample of developed and
 developing countries has narrowed gradually for more
 technologically-sophisticated developing countries. However,
 based on complementary International Monetary Fund Balance
 of Payments data, the patent commercialization divide (as
 indicated by licensing income) has been widening. The paper
 argues that patents, and all forms of intellectual property,
 are an enabling mechanism rather than a defensive right: an
 intangible asset class that can be proactively nurtured and
 managed for greater value extraction to stimulate
 knowledge-based entrepreneurship and growth in developing
 countries. The paper presents multiple case studies of
 alternative monetization strategies to address the
 commercialization divide. These strategies range from
 private, market-driven options to those requiring a greater
 amount of public policy support: from patent securitization
 and patent exchanges (focusing on the United
 States-initiated Intellectual Property Exchange
 International and the Shanghai Silicon Intellectual Property
 Exchange), to the strengthening of technology transfer and
 commercialization infrastructure (focusing on the experience
 of the Association of University Technology Managers and
 Taiwan, China's Intellectual Property Rights
 Institute), to patent litigation support (including South
 Korea's support of patent infringement lawsuit costs
 for small and medium enterprises). The paper also highlights
 areas where further policy research would be helpful.
-
3rd annual Patent Law InstituteInternet Archive; Patent Law Institute (3rd : 2009) (New York, NY : Practising Law Institute, 2009-01-01)960 pages : 23 cm
-
3rd annual Patent Law InstituteInternet Archive; Patent Law Institute (3rd : 2009) (New York, NY : Practising Law Institute, 2009-01-01)960 pages : 23 cm